Multiplexed Diagnostics Market: By Product (Reagents and Consumables, Analyzers), By Application (Disease Diagnostics, Molecular Diagnostics, and Drug Development), By Technology (Very High Density Multiplexed Assays, High Density Multiplexed Assays, Medium Density Multiplexed Assays, Low-Density Multiplexed Assays, and Next Generation Sequencing Assays), By End User (Hospitals, Diagnostic Centers, and Research Centers), and Geography 

Multiplexed Diagnostics Market size was valued at USD 8,921.4 million in 2022, and growing at a CAGR of 16.2% from 2023 to 2029. The global market provides a detailed overview that can be segmented by product, by application, and by end user. By product, the global multiplexed diagnostics market has been segmented into Reagents Consumables and Analyzers. The Reagents and Consumables segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. Based on application, the global multiplexed diagnostics market is segmented into Disease Diagnostics, Molecular Diagnostics, and Drug Development), By Technology (Very High-Density Multiplexed Assays, High Density Multiplexed Assays, Medium Density Multiplexed Assays, Low Density Multiplexed Assays, and Next Generation Sequencing Assays. Among these, the Molecular Diagnostics segment is expected to have the fastest-growing market during the forecast period. Based on end user, the global multiplexed diagnostics market is segmented into Hospitals, Diagnostic Centers, and Research Centers. Hosted segment is the second-largest share during the forecast period. Multiplexed Diagnostics are utilized as a part of examination of biological samples, which are fit for finishing a screening procedure with a solitary run. Multiplexed assay tests are engaged with the discovery and analysis of various illnesses and contaminations, which incorporate growths, immune system ailments, hypersensitivities, and cardiovascular infections.

Multiplexed Diagnostics Market Key Development:

• In Oct 2022, Genes2Me launched Rapi-Q- Point of Care RT PCR for diseases like HPV and Tuberculosis.
• In Oct 2022, Multi-omics Startup Pleno Inc. announced $40 Million in series a funding led by deerfield management with participation by foresite capital.